CD4 and glioblastoma: Similar to the Odc129mer SLP vaccine, in two recent phase I trials evaluating neoantigen vaccines in GBM patients, si of the seven (~86%) detectable neoepitope-specific IFNγ+CD8+ T-cell responses were accompanied by an IFNγ+CD4+ T-cell response to the same immunizing SLP1,2, implicating the clinical significance of CD4+ T-cell help in the immunogenicity of MHC I-restricted neoepitopes.